News
CAI
26.98
-1.24%
-0.34
Weekly Report: what happened at CAI last week (1222-1226)?
Weekly Report · 12/29/2025 09:50
Caris Life Sciences: Stronger Fundamentals, Same Conclusion
Seeking Alpha · 12/24/2025 13:00
Caris Life Sciences Is Maintained at Hold by Canaccord Genuity
Dow Jones · 12/22/2025 12:54
Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30
Benzinga · 12/22/2025 12:45
Caris Life Sciences price target raised to $30 from $28 at Canaccord
TipRanks · 12/22/2025 11:55
Cathie Wood's weekly recap: boots bets on AI biotech, crypto; pares back consumer names
Seeking Alpha · 12/22/2025 11:30
Weekly Report: what happened at CAI last week (1215-1219)?
Weekly Report · 12/22/2025 09:50
Providence Swedish Cancer Institute Joins Caris Precision Oncology Alliance
Reuters · 12/19/2025 13:30
The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute
PR Newswire · 12/19/2025 13:30
J.P. Morgan Reaffirms Their Buy Rating on Caris Life Sciences, Inc. (CAI)
TipRanks · 12/19/2025 09:36
BLSH, SLMT, CAI: Cathie Wood Loads Up on Crypto and Healthcare Stocks, Trims a Consumer Tech Name
TipRanks · 12/17/2025 05:31
Reassessing Caris Life Sciences (CAI) Valuation After Recent Share Price Pullback and Short-Term Rebound
Simply Wall St · 12/16/2025 23:29
BUZZ-U.S. STOCKS ON THE MOVE-Sunrun, PayPal, Caris
Reuters · 12/16/2025 18:45
BUZZ-Caris rises on $1.1 billion deal with Genentech
Reuters · 12/16/2025 17:58
Roche in pact with Caris to discover cancer drug targets
Seeking Alpha · 12/16/2025 17:32
BRIEF-Caris Life Sciences Announces Collaboration With Genentech
Reuters · 12/16/2025 15:00
Caris signs Genentech deal worth up to $1.1 billion for rare cancer targets
Reuters · 12/16/2025 14:19
Caris Life Sciences' Caris Discovery Signs License Agreement With Genentech To Identify, Validate Oncology Targets In Solid Tumor Tissue
Benzinga · 12/16/2025 13:37
Caris Life Sciences partners with Roche’s Genentechh for cancer targets
TipRanks · 12/16/2025 13:35
More
Webull provides a variety of real-time CAI stock news. You can receive the latest news about Caris Life Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.